Article
Cost-Effectiveness of the Dabrafenib Schedule in Combination With Trametinib Compared With Other Targeted Therapies, Immunotherapy, and Dacarbazine for the Treatment of Unresectable or Metastatic Melanoma With BRAFV600 Mutation in Colombia.
Value in health regional issues - 1 Dec 2021
Gil-Rojas Yaneth, Lasalvia Pieralessandro, Hernández Fabián, Castañeda-Cardona Camilo, Castrillón-Correa Johanna, Herrera Daniel, Rosselli Diego
Abstract excerpt
OBJECTIVES: Advanced melanoma accounts for 4% of malignant skin tumors, and approximately 80% of deaths are attributed to it. The most frequent mutation of the RAF gene is BRAFV600, which has been associated with a worse prognosis. The objective of the research was to evaluate the cost-effectiveness of the combined regimen of dabrafenib plus trametinib (D + T) compared with other targeted therapies,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.